Trimel Announces Closing of $10.5 Million Private Placement of Common Shares
21 Février 2014 - 9:44PM
Marketwired
Trimel Announces Closing of $10.5 Million Private Placement of
Common Shares
TORONTO, ONTARIO--(Marketwired - Feb 21, 2014) - Trimel
Pharmaceuticals Corporation (TSX:TRL) announced today that the
previously disclosed private placement of 14,829,676 common shares
("Common Shares"), in aggregate, to First Generation Capital Inc.
and West Face Long Term Opportunities Global Master L.P. for total
gross proceeds of $10,543,000 has been completed.
"We would like to thank each of the subscribers for their
continuing support," stated Tom Rossi, President and Chief
Executive Officer. "These funds will allow management to focus
their efforts on achieving the key operational objectives and
milestones of the company over the coming months."
About Trimel
Trimel is a specialty pharmaceutical company actively developing
medications for male hypogonadism, female sexual dysfunction and
various respiratory disorders. An NDA for CompleoTRT™, a product
utilizing Trimel's licensed bioadhesive intranasal gel technology,
has been accepted for review by the FDA for regulatory approval in
the United States. For more information, please visit
www.trimelpharmaceuticals.com.
Trimel Pharmaceuticals CorporationKenneth G. HowlingChief
Financial Officer(416)
679-0536ir@trimelpharmaceuticals.comwww.trimelpharmaceuticals.com
Trilogy International Pa... (TSX:TRL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Trilogy International Pa... (TSX:TRL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Trilogy International Partners Inc (Toronto Stock Exchange): 0 recent articles
Plus d'articles sur Trimel Pharmaceuticals Corp